Metabolism Platform
GemPharmatech provides animal disease models and genetically humanized models for metabolic diseases, including diabetes mellitus, abnormal lipid metabolism, obesity, and MASH. The company additionally provides a series of in vivo R&D services, with corresponding disease models selected in light of the mechanism of action of the investigational drug.
These models include histopathological analysis, detection of metabolism-related cytokines and inflammatory factors, body weight and food intake, blood glucose, glycosylated haemoglobin (HbA1c), plasma insulin, GTT, and ITT, as well as body composition, bone density, and both indirect and direct metabolic cage tests, which monitor for factors such as CO2 and O2 production, heat, RER and activity, or urine and fecal collection.
